Zobrazeno 1 - 10
of 166
pro vyhledávání: '"Robert A. Falconer"'
Autor:
Francis M. Barnieh, Goreti Ribeiro Morais, Paul M. Loadman, Robert A. Falconer, Sherif F. El‐Khamisy
Publikováno v:
Advanced Science, Vol 11, Iss 34, Pp n/a-n/a (2024)
Abstract Targeted therapy remains the future of anti‐cancer drug development, owing to the lack of specificity of current treatments which lead to damage in healthy normal tissues. ATR inhibitors have in recent times demonstrated promising clinical
Externí odkaz:
https://doaj.org/article/89b2cd1dff6344aabd813f0ac8032b72
Autor:
Louise K. Stevenson, Amy J. Page, Matthew Dowson, Sameh K. ElBadry, Francis M. Barnieh, Robert A. Falconer, Sherif F. El-Khamisy
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 12 (2024)
Classically, ATM is known for its role in sensing double-strand DNA breaks, and subsequently signaling for their repair. Non-canonical roles of ATM include transcriptional silencing, ferroptosis, autophagy and angiogenesis. Angiogenesis mediated by A
Externí odkaz:
https://doaj.org/article/d4199569099e4c3e975aa4fb68e4854c
Autor:
Francis M. Barnieh, Sebastian P. Galuska, Paul M. Loadman, Simon Ward, Robert A. Falconer, Sherif F. El-Khamisy
Publikováno v:
iScience, Vol 26, Iss 11, Pp 108219- (2023)
Summary: Harnessing the differences between cancer and non-cancer tissues presents new opportunities for selective targeting by anti-cancer drugs. CD13, a heavily glycosylated protein, is one example with significant unmet clinical potential in cance
Externí odkaz:
https://doaj.org/article/bd2bf1908dae46818c9cada538aeea92
Publikováno v:
Current Research in Pharmacology and Drug Discovery, Vol 2, Iss , Pp 100017- (2021)
The DNA damage response (DDR) is now known to play an important role in both cancer development and its treatment. Targeting proteins such as ATR (Ataxia telangiectasia mutated and Rad3-related) kinase, a major regulator of DDR, has demonstrated sign
Externí odkaz:
https://doaj.org/article/119315a7ae774e0fb0ba04253dc5fc6e
Autor:
Heike E. Daldrup-Link, Robert A. Falconer, Paul M. Loadman, Jianghong Rao, Sanjiv Sam Gambhir, Edwin Chang, Samuel Cheshier, Siddharta Mitra, Frederick T. Chin, Laura Pisani, Ketan Yerneni, Jessica Klockow, Goreti Ribeiro Morais, Kai Li, Zixin Chen, Suchismita Mohanty
Glioblastoma (GBM) has a dismal prognosis. Evidence from preclinical tumor models and human trials indicates the role of GBM-initiating cells (GIC) in GBM drug resistance. Here, we propose a new treatment option with tumor enzyme-activatable, combine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6cfde44f0d5475ce85a61715b8ac14d
https://doi.org/10.1158/1535-7163.c.6539568.v1
https://doi.org/10.1158/1535-7163.c.6539568.v1
Autor:
Heike E. Daldrup-Link, Robert A. Falconer, Paul M. Loadman, Jianghong Rao, Sanjiv Sam Gambhir, Edwin Chang, Samuel Cheshier, Siddharta Mitra, Frederick T. Chin, Laura Pisani, Ketan Yerneni, Jessica Klockow, Goreti Ribeiro Morais, Kai Li, Zixin Chen, Suchismita Mohanty
In vivo tumorigenic assay for GIC derived from pcGBM39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3441a5004eb6b28880d2e511422ec620
https://doi.org/10.1158/1535-7163.22510302.v1
https://doi.org/10.1158/1535-7163.22510302.v1
Autor:
Jason H. Gill, Paul M. Loadman, Laurence H. Patterson, Michael C. Bibby, Steven D. Shnyder, Catherine S. Siller, Caroline J. Pennington, Dylan R. Edwards, Robert A. Falconer, Jennifer M. Atkinson
Vascular disrupting agents (VDA) offer a strategy to starve solid tumors of nutrients and oxygen concomitant with tumor shrinkage. Several VDAs have progressed into early clinical trials, but their therapeutic value seems to be compromised by systemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0302cc92e687d673ed71302165d977e8
https://doi.org/10.1158/0008-5472.c.6501143.v1
https://doi.org/10.1158/0008-5472.c.6501143.v1
Autor:
Jason H. Gill, Paul M. Loadman, Laurence H. Patterson, Michael C. Bibby, Steven D. Shnyder, Catherine S. Siller, Caroline J. Pennington, Dylan R. Edwards, Robert A. Falconer, Jennifer M. Atkinson
Supplementary Data from Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix Metalloproteinases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8da897f66684da795f7747fe0de6ed95
https://doi.org/10.1158/0008-5472.22385189.v1
https://doi.org/10.1158/0008-5472.22385189.v1
Publikováno v:
ACS Omega, Vol 1, Iss 4, Pp 669-679 (2016)
Externí odkaz:
https://doaj.org/article/b66d13d8313046149de176abd30a754e
Autor:
Katreen A. F. Banisalman, Athina Polykandritou, Francis M. Barnieh, Goreti Ribeiro Morais, Robert A. Falconer
Publikováno v:
The Journal of organic chemistry. 87(21)
Glycosylation of peptides and proteins is a widely employed strategy to mimic important post-translational modifications or to modulate the physicochemical properties of peptides to enhance their delivery. Furthermore, glycosylation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ad8c967a9b0e5588565f774011b4a83
https://pubmed.ncbi.nlm.nih.gov/36265181
https://pubmed.ncbi.nlm.nih.gov/36265181